anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Non-small cell lung cancer (NSCLC) is still the leading cause of cancer death world-wide. Radiation therapy (RT) is one of the most important treatment choices in locally advanced NSCLC. Combination of RT and chemotherapy could improve treatment outcomes. However, the combined modality could not be used in many patients due to severe toxicities. EGFR-TKI shows great efficacy in the treatment of NSCLC, and many phase I/II studies established its safety in combination with RT. This phase II study is to further evaluate the efficacy and safety of the combination of RT and erlotinib in the treatment of locally advanced NSCLC. Eligible patients include patients with stage IIIA/IIIB NSCLC, who are not suitable for or refused to receive concurrent chemoradiotherapy. Eligible patients will receive oral erlotinib (150mg qd)throughout the course of thoracic RT (60-70 Gy). The primary endpoint is progression free survival and the second endpoints are overall survival and any grade III and above toxicities. We are going to recruit 50 patients for this study.
All enrolled subjects passing conditions outlined in Intervention are eligible to be included. WL will be calculated (20 mL/kg body weight) and supplied at the bedside. Patient will have 30 minutes to consume WL, or will be excluded.
Ester-substituted thienotriazolodiazepine compounds represented by general formula (I) (wherein Ar represents pyridyl, phenyl or phenyl having one to three same or different substituents R?1 and R?3, which may be the same or different, each represents hydrogen or C1-4? alkyl, R?2 represents hydrogen, C1-4? alkyl or trifluoromethyl, and R represents C1-18? straight or branched-chain alkyl, C2-18? straight or branched-chain alkenyl, aryl, aryl having one to three same or different substituents, aralkyl, aralkyl having one or more same or different substituents on the aromatic ring or alkyl chain, aralkyl fused with a heterocyclic ring, aralkenyl, aralkenyl having one to three same or different substituents, heteroarylalkyl, or optionally substituted indenylalkyl), pharmaceutically acceptable salts thereof, and their medicinal use are disclosed. These compounds are useful as drugs for treating various diseases induced by thrombocyte activator.
Colchicine is a substrate of the efflux transporter P-glycoprotein (P-gp), and the CYP3A4 metabolizing enzyme. Fatal drug interactions have been reported when colchicine is administered with clarithromycin, a dual inhibitor of CYP3A4 and P-glycoprotein. Toxicities have also been reported when colchicine is administered with inhibitors of CYP3A4 that may not be potent inhibitors of P-gp (e.g., grapefruit juice, erythromycin, verapamil), or inhibitors of P-gp that may not be potent inhibitors of CYP3A4 (e.g., cyclosporine).

Patients with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein and CYP3A4 [see Contraindications (4)].  Combining these dual inhibitors with colchicine capsules in patients with renal and hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. 

Physicians should ensure that patients are suitable candidates for treatment with colchicine capsules and remain alert for signs and symptoms of toxic reactions associated with increased colchicine exposure due to drug interactions. Signs and symptoms of colchicine toxicity should be evaluated promptly and, if toxicity is suspected, colchicine capsules should be discontinued immediately.
FIELD: biotechnology.SUBSTANCE: group of inventions relates to biotechnology. Proposed isolated protein with phosphatase activity, containing the amino acid sequence of at least 365 consecutive amino acids, having at least 98 % identity with SEQ ID NO: 5, the amino acid sequence of 65 consecutive amino acids, having at least 98 % identity with SEQ ID NO: 6, and an amino acid sequence of 54 consecutive amino acids having at least 98 % identity with SEQ ID NO: 7, where the full-size protein contains an amino acid sequence having at least 98 % identity with the full amino acid sequence of SEQ ID NO: 1, when it contains modifications 279L, 328V and 478L. Polynucleotide encoding the specified protein, and a vector containing the specified polynucleotide is proposed. Proposed host cell containing the specified protein, polynucleotide or vector, is a cell CHO. Method is proposed for producing said protein using said host cell. Proposed pharmaceutical composition contains the specified protein for use as a drug for the prevention or treatment of inflammatory diseases, kidney disease or hypophosphatasia.EFFECT: group of inventions allows to obtain a protein with phosphatase activity, with improved thermal stability, improved biodistribution and improved Znindependenceand which may be useful for treating diseases caused by or accompanied by low levels of Zn.21 cl, 35 dwg, 10 ex, 20 tbl
The study is on patients with grade II-IV acute ocular chemical burns (Roper - Hall classification) in the first 2 weeks of injury.

After topical anesthesia, all patients initially will receive first aid therapy; which included irrigation with normal saline to normalize ocular surface PH and removal of early particulate maeuil and debris. After complete examination and obtaining informed consent, the patients will be randomized using a treatment assignment list to either AMT with conventional medical therapy (group A) or medical treatment only (group B). In the patients with bilateral injuries the eyes will be randomized separately. AMT will be performed within 24h of presentation. amniotic membrane will remain in place for 7-14 days. The patients will be examined at days 1, 3, 7, 10, 14, 21, 28 and then biweekly until 3 months and monthly until (1 year in every visit, visual acuity (by sneillen charts), reduction of pain (subjectively) size of corneal epithelial defect (by fluorseein satiny extent of corneal vascularization and opacity, and symblepharon formation will be assessed. Digital photographs at each visit will be obtained.
<P>PROBLEM TO BE SOLVED: To provide 3-substituted-2-(arylalkyl)-1-azabicycloalkane, a method of producing the same, and a therapeutic method using the compound.  <P>SOLUTION: The azabicycloalkane is azabicyclooctane or the like. The aryl group in the arylalkyl moiety thereof is a 3-pyridinyl moiety or a 5-pyrimidinyl moiety, and the alkyl group thereof is a 1-4C alkyl. The substituent at the 3-position of the 1-azabicycloalkane is a functional group such as an amide. The compound exhibits activity at a nicotinic acetylcholine receptor (nAChR), particularly at an a7 nAChR subtype, and is useful in modulating neurotransmission and in the release of a ligand involved in neurotransmission. The compound is effective in preventing or treating conditions and disorders including central nerve system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, and is also effective in treating inflammation, autoimmune disorders, pain, and excess neovascularization (such as one associated with tumor growth).  <P>COPYRIGHT: (C)2011,JPO&INPIT
PURPOSE:To provided the color and appearance having the depth approximate to the depth of a natural tooth by preparing glass raw materials for crown restoration and selecting the same from plural kinds of lightness or combinations of the lightness and saturation as one index and shade guides classified by plural kinds of hues as the other index. CONSTITUTION:Plural kinds of the glass raw materials for crown restoration to yield colored glass ceramics which are different in the lightness or the combinations of the lightness and saturation from each other in the crystallized state of the glass and plural kinds of the compsn. for shading which are different in the hues or the combination of the hues, lightness and saturation are prepd. The glass raw materials for crown restoration and the compsn. for shading are selected according to selection. This glass raw material for crown restoration consists of the compsn. formed by compounding 0.01-17.0wt.% color forming component with 100 pts.wt. glass component. The crown restoring material body consisting of the colored glass ceramics is produced by subjecting a casting to a heat treatment and crystallizing the glass. On the other hand, the shading compsn. is applied on the crown restoring material body and the body is calcined. This stage is repeated at need, by which the crown restoring material of a desired color is obtd.
Dehydration is common in older adults and impacts their clinical outcomes. Chronic dehydration is especially important as it has been under-recognized. This scoping review aimed to summarize the available definitions of chronic dehydration to identify gaps between each definition and discuss future research needs. Four databases (Pubmed, CINAHL, Cochrane Library, Science Direct) were systematically searched for peer-reviewed articles that clearly described the definition of chronic dehydration published from inception to June 8th, 2023. Two researchers reviewed the articles independently, and any disagreement was solved upon discussion. We identified five articles with a wide range of subjects from children to older adults. Chronic dehydration was defined as a state of persistently elevated blood urea levels; weight loss ≥ 1% as a result of fluid loss; a ratio of blood urea nitrogen to creatinine > 20; serum osmolarity ≥ 295 mOsm/kg; and a dehydrated state lasting 72 hours or longer. The definition varied among studies, indicating the need to establish an international consensus on the definition of chronic dehydration.
Stroke is the leading cause of activity limitation among older adults in the United States. NeuroMuscular Electrical Stimulation (NMES) can be used by stroke survivors who do not have enough residual movement to take part in volitional active repetitive movement therapy and does not require expensive equipment or skilled personnel. Two types of NMES are available. The first is cyclic NMES, which electrically activates paretic muscles at a set duty cycle for a preset time period. (This study will employ both "traditional" cyclic stimulation and "sensory-only" stimulation, in which intensity is set at a level to be felt by the patient but insufficient to cause muscle contraction.)In cyclic NMES, the patient is a passive participant and does not assist the NMES by volitionally contracting the muscle during stimulation. The second type encompasses various forms of NMES in combination with biofeedback. For example, in "EMG-triggered" NMES, subjects are "rewarded" with stimulation in response to successful attempts to reach a pre-set level of EMG activity in the affected muscle. There is increased cognitive input and involvement on the part of the patient. The purpose of this study is to first demonstrate the effectiveness of these two types of surface stimulation on decreasing motor impairment and activity limitation; the study also seeks to assess the effect of adding cognitive input to NMES to reduce motor impairment and activity limitation.

Study subjects will be acute stroke survivors. They will participate for a total of eight months, beginning within the first six months after their stroke. Subjects will be randomly assigned to one of three treatment groups and will receive stimulation accordingly: 1) Cyclic stimulation; 2)Sensory-only stimulation; and 3)EMG-triggered stimulation. Members of each treatment group will be given an appropriate NMES device to use for two 40-minute treatment sessions per day, five times per week for eight weeks; for a total of 80 treatment sessions. Stimulation will be applied to ECR and EDC (wrist and finger extensors) on the affected arm. A treatment therapist will visit the patient at home on a weekly basis to monitor subject compliance and to provide feedback on device usage. The primary outcome measure will be the upper extremity portion of the Fugl-Meyer Motor Assessment (FMA), a measure of motor impairment. The modified Arm Motor Ability Test (mAMAT) is a hemiparetic arm-specific measure of activity limitation, and will serve as a secondary outcome measure.

In addition to the baseline visit on day of enrollment, subjects will complete these outcome measurements at the clinic on five other occasions: at mid-treatment (week 5); end of treatment (week 9); and for follow-up visits at one-, three- and six-months post-treatment.
This randomized, double-blind, placebo-controlled dose escalation study will enroll up to 5 cohorts of healthy subjects. Eight subjects will be enrolled in each cohort and will receive a single 2-hour intravenous infusion of CR8020 (6 subjects) or placebo (2 subjects) on Day 1. Subjects will be dosed in pairs of two. Once all subjects in a cohort have completed Study Day 8, the preliminary safety data will be reviewed. Provided that no safety issues are identified, dose escalation to the subsequent cohort may be permitted. After the completion of Cohort 5 enrollment, and the preliminary safety and tolerability of the 50mg/kg dose is demonstrated, a sixth cohort will be enrolled. Cohort 6 will be comprised of 24 subjects (randomized 5:1 to CR8020 30 mg/kg or placebo) who will receive 2-hour intravenous infusions on Days 1 and 8.
INTRODUCTION: Cerebral ischemia reperfusion injury (CIRI) often leads to deleterious complications after stroke patients receive reperfusion therapy. Exercise preconditioning (EP) has been reported to facilitate brain function recovery. We aim to explore the specific mechanism of EP in CIRI.
METHODS: Sprague-Dawley rats were randomized into Sham, middle cerebral artery occlusion (MCAO), and EP groups (n = 11). The rats in the EP group received adaptive training for 3 days (10 m/min, 20 min/day, with a 0° incline) and formal training for 3 weeks (6 days/week, 25 m/min, 30 min/day, with a 0° incline). Then, rats underwent MCAO surgery to establish CIRI models. After 48 h, neurological deficits and cerebral infarction of the rats were measured. Neuronal death and apoptosis in the cerebral cortices were detected. Furthermore, RNA sequencing was conducted to investigate the specific mechanism of EP on CIRI, and qPCR and Western blotting were further applied to confirm RNA sequencing results.
RESULTS: EP improved neurological deficit scores and reduced cerebral infarction in MCAO rats. Additionally, pre-ischemic exercise also alleviated neuronal death and apoptosis of the cerebral cortices in MCAO rats. Importantly, 17 differentially expressed genes (DEGs) were identified through RNA sequencing, and these DEGs were mainly enriched in the HIF-1 pathway, cellular senescence, proteoglycans in cancer, and so on. qPCR and Western blotting further confirmed that EP could suppress TIMP1, SOCS3, ANGPTL4, CDO1, and SERPINE1 expressions in MCAO rats.
CONCLUSION: EP can improve CIRI in vivo, the mechanism may relate to TIMP1 expression and HIF-1 pathway, which provided novel targets for CIRI treatment.
Rhodiola crenulata for the first treatment period and placebo for the second treatment period, with a washout period of 4 months. Overall study population were 120 subjects, who were randomised and allocated into 2 sequences.
Diagnostic and therapeutic allergenic extracts are intended to be administered by a physician who is an allergy specialist and experienced in allergenic diagnostic testing and immunotherapy and the emergency care of anaphylaxis. 

This product should not be injected intravenously. Deep subcutaneous routes have been safe. Sensitive patients may experience severe anaphylactic reactions resulting in respiratory obstruction, shock, coma and/or death. (See Adverse Reactions)

Serious adverse reactions should be reported to Nelco Laboratories immediately and a report filed to: MedWatch, The FDA Medical Product Problem Reporting Program, at 5600 Fishers Lane, Rockville, Md. 20852-9787, call 1-800-FDA-1088.

Extreme caution should be taken when using allergenic extracts for patients who are taking beta-blocker medications. In the event of a serious adverse reaction associated with the use of allergenic extracts, patients receiving beta-blockers may not be responsive to epinephrine or inhaled brochodialators.(1)(See Precautions)

Allergenic extracts should be used with caution for patients with unstable or steroid-dependent asthma or underlying cardiovascular disease. (See Contraindications)
The invention relates to a Chinese medicinal blood glucose reducing tablet for treating diabetes.. The Chinese medicinal blood glucose reducing tablet comprises superfine powder and is prepared from fourleaf ladybell root, dwarf lilyturf tuber, Common anemarrhena, rehmannia root, noble dendrobium stem herb, gypsum, baikal skullcap root, Chinese goldthread rhizome, snakegourd root, Chinese magnoliavine fruit, milkvetch root, moutan bark, dan-shen root and licorice root. The tablet is prepared from the following steps: taking half of each of gypsum, baikal skullcap root, snakegourd root, milkvetch root, moutan bark and dan-shen root, adding Chinese goldthread rhizome, pulverizing into superfine powder with beili pulverizer, decocting the rest raw materials with water twice, mixing decoctions, filtering, concentrating filtrate to thick extract with relative density of 1.25-1.30 (60-70 DEG C), adding superfine powder, and processing into tablets. The tablet is administered for 3 times every day, with 3-4 tablets per time. The Chinese medicinal blood glucose reducing tablet has low cost and is easy for preparation and convenient for administration, the raw materials are easily accessible, and the effective ingredients can dissolve out and be digested, absorbed and utilized to a maximum extent. The tablet has the effects of nourishing yin, moistening dryness, turning recession trend of islet functions, and promoting revivification of islet cells. In addition, through administration of the tablets, patients need not to suffer from the bitter taste of traditional decoction.
BACKGROUND: At present, there is no golden standard for treatment of extracranial arteriovenous malformations (AVMs) and recurrence remains a major challenge with limited available evidence on the associated factors. This study aimed to evaluate the effectiveness of surgical treatment options, in terms of size reduction, symptoms, and early recurrence in patients treated surgically for AVMs.
METHODS: A retrospective cohort study was conducted to evaluate patients with AVMs following surgical treatment in 2 centers from 2005 to 2020. Posttreatment lesion size and symptoms, as well as recurrence, were assessed. Multiple regression analysis was performed to identify factors associated with recurrence.
RESULTS: Forty-four surgical treatment cases in 31 patients were assessed with a mean follow-up duration period of 67.9 ± 39.5 months. Treatment included total resection in 26 cases (59.1%) and partial resection 18 (40.9%), with free flap coverage used in 19 cases (43.2%). No acute exacerbation following treatment was observed in our cohort. Total resection significantly reduced posttreatment lesion size ( P < 0.001), symptoms ( P < 0.001), and recurrence (20.0%, P = 0.03). The recurrence rate was significantly higher after partial resection (73.7%, P = 0.03). Total resection was identified as an associated factor for significantly reduced AVM recurrence (odds ratio: 0.12; 95% confidence interval: 0.03, 0.52). However, the use of free flaps did not significantly reduce recurrence, post treatment size or improve AVM symptoms.
CONCLUSIONS: Total resection is the optimal treatment for AVMs. Free flaps are useful in covering large defects but the regulative effect of free flap remains controversial.
OBJECTIVE: Sternotomy has been the gold standard incision for surgical revascularization but may be associated with chronic pain and sternal malunion. Minimally invasive coronary artery bypass grafting allows for complete surgical revascularization through a small thoracotomy in selected patients. There is a paucity of long-term data, particularly functional outcomes, for patients who underwent minimally invasive coronary artery bypass grafting.
METHODS: Patients (N = 566) who underwent minimally invasive coronary artery bypass grafting at a single institution over a 17-year period were prospectively followed. The primary outcome was survival. At late follow-up, patients were contacted for a questionnaire on functional outcomes. Multivariable Cox proportional hazard model identified correlates of the primary outcome.
RESULTS: Clinical follow-up was complete for 100% of patients (mean 7.0 ± 4.4 years); a follow-up questionnaire was also completed for 83.9% (N = 427) of live patients. Fifty percent of patients (N = 283) had undergone multivessel grafting. At 12 years, survival for the entire cohort was 82.2% ± 2.6%. On late follow-up questionnaire, 12 patients (2.8%) had greater than Canadian Cardiovascular Score Class II angina and 19 patients (4.5%) had greater than New York Heart Association Class II symptoms. More than 98% of patients did not have pain related to the incision site. Cox proportional hazards analysis identified older age, peripheral vascular disease, prior myocardial infarction, left ventricular dysfunction, cancer in the past 5 years, intraoperative transfusion, and hybrid revascularization as correlates of mortality during follow-up.
CONCLUSIONS: Minimally invasive coronary artery bypass grafting is a safe and durable alternative to sternotomy coronary artery bypass grafting in selected patients, with excellent short- and long-term outcomes, including for multivessel coronary disease. At long-term follow-up, the proportion of patients with significant symptoms and incisional pain was low.
SCLC accounts for approximately 15% of new cases of lung cancer, and an estimated 33,000 cases are expected to be diagnosed in the United States in 2016. Compared to NSCLC, SCLC typically has a more rapid doubling time, a higher growth fraction, and earlier development of distant metastases. Patients with limited stage (LS) disease are treated with curative intent using definitive, concurrent chemotherapy and thoracic radiotherapy. For patients with extensive stage (ES) disease, systemic chemotherapy can prolong survival in most cases, however long-term survival is rare. Despite the activity of several agents in SCLC, an etoposide plus platinum (i.e. cisplatin) doublet regimen remains the standard of care in the first-line setting because of its higher activity compared to other chemotherapy regimens, as well as the ease of combining it with radiation. Initial response rates may be as high as 70-90% in LS-SCLC and 50-70% in ES-SCLC. However, the disease typically recurs rapidly which is reflected by median survival rates of 9 to 11 months for ES-SCLC and a 2-year survival rate of less than 5%.

This study has a 3 + 3 design that will be used to assess the safety of SGI-110 given prior to flat doses of durvalumab (1500 mg) and tremelimumab (75 mg). The starting dose of SGI-110 will be 30 mg/m2 (dose level 0) and the target dose that is predicted to be safe and most effective will be 45 mg/m2 (dose level 1). These doses have been chosen based on safety and efficacy data from phase 1 clinical trials in other solid tumors, as described above. Patients enrolled in any given dose level will be evaluated for safety (adverse events monitoring) and efficacy. There will be mandatory pre- and on-treatment tumor biopsies performed in alternating fashion on cycle 1 day 8 +/- 2 days or cycle 2 day 8 +/- 2 days. The dose-limiting toxicity (DLT) observation period will last for 4 weeks (28 days) and ends on C2D1. Delayed serious immune-mediated adverse events will also be monitored but will not be considered dose limiting toxicities.